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Abstract: Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). 
To investigate the correlation between the progression of COPD and plasma biomarkers of chronic inflammation and oxi-
dative injury, blood samples were obtained from healthy volunteers (HV, n = 14) and stabilized COPD patients. The pa-
tients were divided into three groups according to their GOLD stage (II, n = 34; III, n = 18; IV, n = 20). C-reactive protein 
(CRP), protein carbonyls (PC), malondialdehyde (MDA), susceptible lipoperoxidation of plasma substrates (SLPS), and 
myeloperoxidase activity (MPO) were measured. The plasma concentration of SLPS was measured as the amount of 
MDA generated by a metal ion-catalyzed reaction in vitro. PC, SLPS, and CPR were increased significantly (p < 0.001) in 
COPD patients when compared to HV. MDA concentrations and MPO activities were not significantly different from 
those of the HV group. In conclusion, increased oxidation of lipids and proteins resulting in a progressive increase in the 
amount of total plasma carbonyls and oxidative stress the presence of oxidative stress during COPD progression, con-
comitant with an increased oxidation of lipids and proteins resulting in a progressive and significant increase in the 
amount of total carbonyls formed from lipid-derived aldehydes and direct amino acid side chain oxidation in plasma, may 
serve as a biomarker and independent monitor of COPD progression and oxidative stress injury. 
Keywords: Chronic obstructive pulmonary disease (COPD),  oxidative stress, protein carbonyls, reactive oxygen species 
(ROS), lipoperoxidation of plasma substrates (SLPS). 
INTRODUCTION 
  Chronic obstructive pulmonary disease (COPD) is a 
major cause of chronic morbidity and mortality throughout 
the world, and the prevalence and mortality of this disease 
are predicted to increase in future decades. A unified, inter-
national effort is required to reverse these trends. For educa-
tional purposes, the Global Initiative for Chronic Obstructive 
Lung Disease, a classification of disease severity into four 
stages, is recommended: GOLD I, mild; GOLD II, moderate; 
GOLD III, severe; GOLD IV, very severe. Oxidative stress 
has been implicated in the pathogenesis and progression of 
COPD
  [1]. Reactive oxygen species (ROS) from inhaled 
cigarette smoke or those endogenously formed by inflamma-
tory cells constitute an increased intrapulmonary oxidant 
burden. Data from in vitro experiments and in vivo studies 
indicate that two general effects of oxidative stress are rele-
vant to COPD. Oxidative stress causes structural changes to 
essential components of the lung, contributing to irreversible 
damage to both the parenchyma and the airway wall 
 [2]. 
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  ROS are generated by leukocytes in the blood or air 
spaces, or inhaled in the form of environmental pollutants 
including cigarette smoke
 [3], particulate matter, and wood 
smoke. ROS are scavenged by enzymatic and non-enzymatic 
antioxidants. Oxidant/antioxidant imbalance resulting from 
the increased production of ROS leads to biomolecular dam-
age by the direct attack of ROS during oxidative stress. Con-
sequences of oxidative stress include adaptation of the cell or 
organism by up-regulation of defence systems including 
induction of antioxidant enzymes to provide limited protec-
tion against oxidative damage
 [4]. Additional consequences 
include cell injury involving oxidative damage to molecular 
targets including lipids, DNA, proteins, and carbohydrates. 
Oxidative damage can also occur during adaptation, but not 
all injuries caused by oxidative stress are oxidative. Damage 
to biomolecules can induce structural modifications; these 
are frequently observed in proteins
 [5]. Such modifications 
can be accompanied by a decrease in the protein’s biological 
activity or receptor recognition and can result in changes in 
ion levels (e.g., Ca
2+) or activation of proteases. Thus, the 
cell may (i) recover from oxidative damage by repairing or 
replacing the damaged molecules, (ii) survive with persistent 
oxidative damage, or (iii) undergo cell death by apoptosis or 
necrosis, particularly if there is oxidative damage to DNA. 62    The Open Respiratory Medicine Journal, 2009, Volume 3  Torres-Ramos et al. 
  Chronic oxidative stress occurs during the progression of 
COPD. This is due in part to the continuous generation of 
ROS by neutrophils that are activated as a consequence of 
the chronic inflammatory process. This condition is aggra-
vated by intermittent activation from other causes including 
cigarette smoke
 [3], air pollution, and deficient antioxidant 
mechanisms in certain patients. We measured the biomarkers 
of oxidative injury (see below) and C-reactive protein 
(CRP), a marker of systemic inflammation, in the plasma of 
COPD patients. The obtained values were related to forced 
expiratory volume in one second (FEV1), forced vital capac-
ity (FVC), and the (GOLD) stage, which is a prognostic 
indicator of mortality risk according to the Global Initiative 
for Chronic Lung Disease [6]. Relationships between the 
inflammatory process, oxidative stress, and the progressive 
decrease of lung function were investigated. 
  Biomarkers of ROS in the plasma can potentially be used 
to evaluate both the injury and degradation of circulating 
biomolecules and endothelial cell membranes. These bio-
markers can not only determine the extent of oxidative in-
jury, but also identify the source of the oxidant and the 
chemical nature of the damage to biomolecules (lipids, pro-
teins, carbohydrates etc.), including modifications and 
breakage. The amount of biomarkers in the plasma depends 
on the number of susceptible substrates for ROS, including 
hormones and lipoproteins that induce lipoperoxidative and 
chemical modifications, especially in phospholipids and 
proteins. Stimulated neutrophils generate superoxide and its 
dismutation product, hydrogen peroxide, and release mye-
loperoxidase (MPO)
  [7]. Myeloperoxidase, in addition to 
oxidizing classical peroxidase substrates to radical interme-
diates, has the unique property of converting chloride to 
hypochlorous acid (HOCl)
 [8], which is considered to be the 
most powerful oxidant generated by neutrophils in associa-
tion with endothelial dysfunction. 
  The results obtained from this study indicate that the 
progression of COPD (GOLD stage) correlates with an in-
crease in protein carbonylation, the amount of susceptible 
lipoperoxidation of plasma substrates (SLPS) for lipoperoxi-
dation  in vitro induced by a metal ion-catalyzed reaction, 
total leukocytes, neutrophil count, and CRP levels. On the 
contrary, the levels of thiobarbiturate-reactive substances 
(TBARs), including MDA, 4HNE, and acrolein, do not cor-
relate with COPD, due in part to the interaction between the 
end products of lipoperoxidation with proteins contributing 
to increased protein carbonylation. 
METHODS 
  Seventy-two patients with COPD who fulfilled the crite-
ria of the Global Initiative for Chronic Obstructive Pulmo-
nary Disease
 [1] were recruited from our respiratory emer-
gency service after acute exacerbation. The patients were 
stabilized and hospitalized for treatment with methyl-
prednisone, oxygenation, and antibiotics according to the 
GOLD guide. After eight days of hospitalization with treat-
ment, the sample of blood for the study was taken on the day 
before the patients were discharged. The patients were classi-
fied as moderate (II), severe (III), or very severe (IV) as 
evaluated by airflow limitation. The control group was com-
posed of 14 healthy non-smoking volunteers who had a 
negative history of allergies (i.e., negative responses to skin 
prick tests for common allergens), normal spirometry results, 
normal FEV1/FVC ratios, no history of any disease, and were 
not receiving medical treatment for any reason. All subjects 
gave informed, written consent, and the protocol was ap-
proved by the ethics committee of the institute (C-03-04). 
  Blood samples (5 mL) from both healthy volunteers and 
COPD patients were obtained by venipuncture and centri-
fuged. The plasma was utilized for assays of biomarkers. 
Myeloperoxidase activity was evaluated by oxidation of 
tetramethylbenzidine; the absorbance was measured at 
655nm [9]. To evaluate lipoperoxidation, 1,1,3,3-tetrameth-
oxypropane (Sigma-Aldrich, MO) was used as a standard. 
Aliquots of plasma were used to measure thiobarbituric-
reactive substances (TBARs) at 532 nm, and the obtained 
values were expressed as pmoles of malondialdehyde 
(MDA) per mg of dry weight
  [10]. Protein damage was 
evaluated by determining free carbonyl levels
 [11] with pro-
tein determination used as the reference parameter
 [12]. 
  Plasma susceptible lipoperoxidation of plasma substrates 
(SLPS) in vitro is a technique used to measure the lipoper-
oxidation of aldehydes in an aliquot of plasma by metal ion-
catalyzed oxidation. This method is conducive to ROS gen-
eration with the concomitant oxidation of substrates, espe-
cially unsaturated fatty acids in lipids and proteins. The 
lipoperoxidation end products arise from the presence of 
unsaturated fatty acids, mainly circulating as phospholipids. 
For SLPS quantification [13], five L of plasma were mixed 
with 5mM H2O2, 5mM FeCl2 (for hydroxyl radical genera-
tion), and 950 L Trizma-Preset buffer, 7.2 mM, pH 8.0, to a 
final volume of 1.0 ml. The mixture was incubated for 15 
min at 37°C. The reaction was stopped by adding 1 mL 
0.375% thiobarbithuric acid (TBA) in 0.2 N HCl and heating 
in a steam bath for 15 min. Finally, 0.5 mL of 0.2 N HCl was 
added. The tubes were cooled and the absorbance was meas-
ured at 532 nm (malondialdehyde, MDA). 1,1,3,3-tetrameto-
xipropano (Sigma Aldrich, MO) was used as the standard. 
  Aliquots of plasma were simultaneously utilized for 
clinical chemical determinations including automated white 
blood cell and differential counts (CELL-DYN 3700 Abbott 
Laboratories. Illinois-USA). C reactive protein (CRP) levels 
were measured by nephelometry. 
  Data are expressed as the mean ± standard deviation. 
One-way ANOVA and Bonferroni's multiple comparison 
test, linear regression, and Pearson correlation were used for 
statistical analysis. Differences were considered significant 
for p < 0.05. Data analyses were performed using the Statis-
tical Package for Social Sciences (version 10.0 for Windows; 
SPSS Inc., Chicago, Ill). 
RESULTS 
  The general and clinical characteristics of the healthy 
volunteers (HV) and COPD patients are shown in Table 1. 
  The total and differential leukocyte counts are shown in 
Fig. (1a,  1b). There was a highly significant increase   
(p < 0.0001) in both total and neutrophil leukocyte number 
associated with each stage of COPD, in accordance with the 
GOLD classification. The number of neutrophils (Fig. 1b; 
3,738 ± 685 neutrophils/mL) and total leukocytes (Fig. 1a; 
6,883 ± 657 cells/mL) was significantly lower (p < 0.01) in 
GOLD II patients than in GOLD IV patients (Fig. 1a: 10,050 Serum Biomarkers in COPD Evolution  The Open Respiratory Medicine Journal, 2009, Volume 3    63 
± 804 cell/mL and Fig. 1b: 7,350 ± 745). The differences 
were also significant when healthy volunteers were com-
pared with GOLD IV patients (p < 0.001). Leukocytosis in 
GOLD IV patients (10,050 ± 804 cells/mL) was increased by 
1.7-fold, and the neutrophilia (7,350 ± 745 cell/mL) was 
increased by 2.4-fold when compared to healthy volunteers. 
The leukocyte counts in GOLD IV patients were signifi-
cantly higher than in GOLD II patients. The plasma concen-
trations of expressed lipoperoxidation products (pmoles 
MDA/mg dry weight) were measured at each GOLD stage. 
Plasma MDA values for groups HV, II, III and IV were 
0.1406 ± 0.01452, 0.1613 ± 0.01334, 0.1148 ± 0.00867 and, 
0.1049 ± 0.00486, respectively, and the MPO values were 
74.52 ± 15.61, 58.91 ± 5.926, 48.90 ± 7.861, and 49.17 ± 
5.844, respectively. Since the MDA and MPO values did not 
correlate with disease progression, these data are not shown 
in the figures. 
 Fig.  (2) shows the plasma concentrations of C-reactive 
protein (mg/dl). The values for GOLD II, III and IV stages 
were significantly greater than those in healthy volunteers. 
There was a significant increase in the C-reactive protein 
concentration in GOLD III patients when compared to 
healthy volunteers (0.44 ± 0.06 versus 0.17 ± 0.04 mg/dl). 
 Fig.  (3) shows that the concentration of free carbonyls in 
proteins was higher in COPD patients at all stages than in 
healthy volunteers (p < 0.001). The values in GOLD II pa-
tients (0.67 ± 0.03 nmol/mg protein) were 73% lower than 
those in GOLD IV patients (0.92 ± 0.04 nmol/mg protein). 
Fig. (3b) shows a significant correlation between the car-
bonyl concentration and CRP; the correlation coefficient was 
0.3356 (p < 0.05). 
  Plasma lipidic substrates (SLPS), mainly phospholipids 
that induce metal ion-catalyzed lipoperoxidation in vitro, can 
be used to measure of the amount of MDA produced. Fig. 
(4) shows that the SLPS level is dependent on the concentra-
tion of available oxidant substrates. The amount of MDA 
generated from an aliquot of plasma was significantly higher 
for patients in all stages of GOLD when compared to the 
control group (p < 0.0001). Values in GOLD II patients 
(0.01136 ± 0.00159 pmol MDA/mg dry weight) were 79.4%  
 
lower than in patients in the GOLD IV stage (0.01413 ± 
0.0001 pmol MDA/mg dry weight). 
(a) 
 
(b) 
 
Fig. (1). Inflammation markers (a) The number of leukocytes (b) 
The number of neutrophils. 
DISCUSSION 
  According to the definition of the American Thoracic 
Society, COPD is characterized by reduced maximum   
 
Table 1.  Demographic Data and Pulmonary Function Tests for Patients with Different COPD Severities and Healthy Volunteers 
 
Parameters  Healthy Volunteers 
(n = 14) 
GOLD II 
(n = 34) 
GOLD III 
(n = 18) 
GOLD IV 
(n = 20) 
p 
Sex F/M  7/7  23/11  11/7  7/13   
Age (yr)  54 ± 4.6  67 ± 1.476  68 ± 2.077  66 ± 2.478  p<0.001 
*BMI (Kg/m
2)  25.70 ± 0.89  26.50 ± 0.643  26.83 ± 1.065  23.95 ± 1.31  NS 
Packyears  -----  53 ± 16  56 ± 12  55 ± 11  ----- 
†FEV1 (%)  104.4 ± 11.5  59.21 ± 1.557  42.00 ± 2.10  36.33 ± 5.75  p<0.0001 
FEV1/§FVC (%)  83.3 ± 5.0  53.86 ± 1.37  44.92 ± 3.31  33.75 ± 5.37  p<0.0001 
*Body mass index. 
†Forced expiratory volume in one second. 
§Forced vital capacity. 
Data are expressed as mean ± SD. 64    The Open Respiratory Medicine Journal, 2009, Volume 3  Torres-Ramos et al. 
 
Fig. (2). The plasma concentrations of C-reactive protein. 
(a) 
 
(b) 
 
Fig. (3). (a) concentration of free carbonyls measured at each of the 
GOLD stages (b) correlation between the protein carbonyl concen-
tration and C-reactive protein level. 
 
Fig. (4). Susceptible lipoperoxidation of plasma substrates (SLPS). 
expiratory flow and slowed forced emptying of the lungs due 
to various combinations of airway disease and emphysema
 
[14]. This definition, as well as those published by many 
other societies and organizations
 [15], focuses exclusively on 
the lungs. Thus, it is not surprising that only pulmonary 
variables such as forced expiratory volume in one second 
(FEV1) or arterial oxygen tension (PaO2), have been consid-
ered in the evaluation and prognosis of this disease and that 
current therapeutic approaches almost exclusively target the 
lungs
 [1, 14, 15]. 
  The focus on lung prognostics and therapy is beginning 
to change because several recent studies have indicated that 
COPD is often associated with significant extrapulmonary 
abnormalities, the so-called “systemic effects of COPD”. 
There is an increasing realization that these systemic effects 
are clinically relevant and may contribute to a better under-
standing and management of the disease. Skeletal muscle 
dysfunction (SMD), considered a major systemic effect of 
COPD, contributes significantly to exercise limitation in 
these patients
  [16]. The identification of weight loss and 
SMD as systemic effects of COPD have drawn attention to 
the importance of nutritional support with vitamins and 
meals rich in antioxidants, often combined with exercise 
programs, to improve the quality of life and prognosis of 
these patients
 [17]. The results of the present study are con-
sistent with several recent reports that have associated COPD 
not only with an abnormal inflammatory response of the 
lung parenchyma
 [18], but also with systemic inflammation 
including systemic oxidative stress, activation of circulating 
inflammatory cells, and increased levels of proinflammatory 
cytokines
 [19]. The systemic inflammatory response, meas-
ured as the number of leukocytes and differential leukocyte 
count, increased significantly with the stage of COPD pro-
gression (Fig. 1). Patients in GOLD IV had higher counts of 
circulating inflammatory cells than healthy controls or 
GOLD II or III patients. Carbonyl concentrations were corre-
lated with the CRP concentration (Fig. 3b), which was also 
highest in patients in stage IV of the disease. The systematic 
increase of CRP is considered to be a representative bio-
marker for chronic inflammation. COPD progression is di-
rectly associated with chronic inflammation. Fig. (3) shows 
the relationship between molecular damage to plasma pro-
teins and the stage of the disease progression in our patients. 
This result suggests that COPD evolution corresponds to an 
increase in protein carbonyls and CRP. The initial or acute  
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oxidative injury to plasma proteins is characterized by an 
increase in aromatic amino acid hydroxyl groups and the 
formation of quinones with oxide reduction properties. After 
what can be considered chronic exposure of proteins to ROS, 
the amountlevel of protein carbonyl groups increases. Oxida-
tive damage results in altered structure
 [5] and function
 of 
circulating proteins, leading to altered antigenicity and im-
mune responses, contraction of smooth muscle, impairment 
of  -adrenoreceptor function, stimulation of airway secre-
tion, and activation of mast cells
  [20]. Protease inhibitors 
such as 1-proteinase inhibitor and secretory leukoprotease 
inhibitor can be inactivated by ROS. These events are con-
sidered critical for the protease/anti-protease imbalance that 
occurs in the pathogenesis of emphysema and correlates with 
the progression of COPD
 [16]. Skeletal muscle dysfunction 
in COPD is characterized by two different, but possibly 
related phenomena: 1) the net loss of muscle mass and in-
trinsic muscular phenomena, and 2) the dysfunction or mal-
function of the remaining muscle. Muscle malfunction may 
be secondary to intrinsic muscle alterations and/or oxidative 
injury of proteins by ROS that the muscle generates. Intrinsic 
muscle alterations include increased mitochondrial genera-
tion of ROS due to electron transport dysfunction
 [21] and 
loss of contractile proteins. Oxidative injury may be due to 
alterations in the muscle environment (hypoxia, hypercapnia, 
acidosis and oxidative stress) that result from the abnormali-
ties of pulmonary gas exchange that characterize COPD
 [18]. 
  The concentration of MDA and activity of MPO were not 
significantly different between COPD patients and healthy 
volunteers; this may be due to the variability in the data. 
Chronic inflammation is shown by increased CRP levels in 
Fig. (2) and protein injury in Fig. (3). This biomarker of 
oxidative stress injury is induced in acute processes such as 
ischemia-reperfusion injury that are accompanied by in-
creased lipoperoxidation. 
  Direct protein carbonylation concomitant with COPD 
progression under oxidative stress conditions can occur 
through a variety of reactions. Oxidation of amino acid side 
chains under oxidative stress conditions causes the formation 
of oxo acids and aldehydes with the same or one less carbon 
atom than the parent amino acid (e.g., Val, Lys, Ile) [22]. 
Alternatively, protein carbonylation can result from an indi-
rect mechanism involving hydroxyl radical-mediated oxida-
tion of lipids. Polyunsaturated acyl chains of phospholipids 
are highly susceptible to peroxidation and breakdown 
through non-enzymatic/Hock cleavage to form a variety of 
lipid-derived aldehydes and ketones [23]. Recent studies 
suggest that protein carbonylation is more commonly de-
rived from lipid-derived aldehydes than through direct amino 
acid side chain oxidation [24]. Fig. (4) shows that the plasma 
from COPD patients contained higher concentrations of 
substrates that generate reactive aldehydes; these substrates 
may form adducts with circulating proteins, thus independ-
ently increasing protein carbonylation by oxidizing the side 
chains of amino acids (Fig. 3). Generated products such as 
malondialdehyde (MDA), acrolein [25], and 4- hy-
droxynonenal selectively modify histidine and lysine mole-
cules by Michael addition [26]. With MDA, Schiff base 
formation and Michael addition appear to be simultaneous, 
thus cross-linking lysine residues. The formation of adducts 
between proteins and MDA [27], utilizing only one of its 
two carbonyls in the Schiff reaction with the amine groups of 
proteins, creates new carbonyls under oxidative stress condi-
tions. The absence of significant changes in plasmatic MDA 
in COPD patients when compared to HV subjects could 
explain the increased formation of protein adducts shown as 
carbonyls in the COPD group (Fig. 3). 
  The COPD group also showed increased levels of 
plasma-susceptible oxidation-lipidic substrates (SLPS), 
which are fundamentally circulating phospholipids (Fig. 4). 
  In conclusion, these results suggest possible progressive 
changes in oxidative stress and inflammation resulting from 
acute characteristics (lipoperoxidation) of chronic oxidative 
stress. This involves damage to circulating proteins concomi-
tant with intracellular oxidative stress, and the systemic 
consequences include skeletal muscle dysfunction apparent 
during the progression of COPD. Finally, we propose that 
plasma carbonyl concentration and CRP can be considered 
biomarkers of injury and the inflammatory process. These 
markers should accompany spirometry for assessment of the 
decreased respiratory function and molecular injury related 
to the GOLD stages of COPD progression. An additional 
longitudinal study that includes more patients and lipid pro-
files, including total phospholipids, lipoproteins, and apopro-
tein quantifications, must be carried out to further validate 
our proposal. 
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ABBREVIATIONS 
COPD  =  Chronic Obstructive Pulmonary Disease 
ROS  =  Reactive oxygen species 
GOLD  =  Global Initiative for Chronic Lung Disease 
FEV1  =  Forced expiratory volume in one second 
FVC  =  Forced vital Capacity 
CRP =  C-reactive  protein 
PC =  Protein  carbonyls 
MDA =  Malondialdehyde 
SLPS  =  Susceptible lipoperoxidation of plasma  
     substrates 
MPO =  Myeloperoxidase 
HOCl =  Hypoclorous  acid 
TBARs  =  Thiobarbituric reactive substances 
ROS  =  Reactive oxygen species 
4HNE =  4-hidroxinonenal 
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